Fusion rate and clinical outcome in anterior lumbar interbody fusion with beta-tricalcium phosphate and bone marrow aspirate as a bone graft substitute. A prospective clinical study in fifty patients.
Bone graft substitutes have been successfully used in posterolateral lumbar fusion, anterior cervical fusion and animal studies. This study has been conducted to assess the safety and efficacy of β-tricalcium phosphate (β-TCP) in instrumented anterior lumbar interbody fusion (ALIF) procedure. In a prospective clinical study, ALIF cages were prefilled with β-TCP and additionally fixated with posterior pedicle screw. Computed tomography (CT) and X-rays were performed one year after surgery. Fusion was assessed and functional status was evaluated before and one year after surgery. X-ray evaluation showed a definite fusion in 85.48 % of treated levels. CT assessment showed anterior and posterior intersegemental bone bridging in 77.78 % of treated levels. The X-ray fusion rate presented is comparable with those published for ALIF procedures with bone graft. Fusion rates β-TCP are similar to autologous bone. ALIF with β-TCP and additional posterior fixation is a safe and effective procedure.